• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期治疗决策对多发性硬化症患者未来收入的重要性。

Importance of early treatment decisions on future income of multiple sclerosis patients.

作者信息

Kavaliunas Andrius, Manouchehrinia Ali, Gyllensten Hanna, Alexanderson Kristina, Hillert Jan

机构信息

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Karolinska University Hospital, Stockholm, Sweden.

出版信息

Mult Scler J Exp Transl Clin. 2020 Oct 7;6(4):2055217320959116. doi: 10.1177/2055217320959116. eCollection 2020 Oct-Dec.

DOI:10.1177/2055217320959116
PMID:33110615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7564625/
Abstract

BACKGROUND

Early initiation of disease-modifying treatment (DMT) is associated with better disability outcomes in multiple sclerosis (MS). However, little is known of how treatment decisions affect socio-economic outcomes.

OBJECTIVE

To estimate the long-term impact of early initiation of DMT on the income of MS patients.

METHODS

In total, 3610 MS patients were included in this register-based cohort study. We measured the association between the time to treatment and the outcome, defined as time from treatment initiation to a 95% decrease in annual earnings compared to each patient´s baseline level. Additionally, the association between time to treatment and increase of social benefits (sickness absence, disability pension) was investigated. A Cox model was adjusted for sex, onset age, education, family situation, country of birth, living area, and disability.

RESULTS

MS patients initiating treatment later had a higher risk of reaching the outcome- those who started treatment after 2 years from MS onset lost 95% of their earnings sooner (HR, 1.19; 95% CI, 1.04-1.37). Furthermore, risk to receive an annual compensation of SEK 100,000 (≈EUR 10,500) was higher for the delayed treatment group.

CONCLUSION

Early treatment initiation in MS is associated with better socioeconomic outcome, adding to previous studies showing benefits regarding disability.

摘要

背景

在多发性硬化症(MS)中,早期开始疾病修饰治疗(DMT)与更好的残疾结局相关。然而,对于治疗决策如何影响社会经济结局却知之甚少。

目的

评估早期开始DMT对MS患者收入的长期影响。

方法

本基于登记的队列研究共纳入3610例MS患者。我们测量了治疗时间与结局之间的关联,结局定义为从治疗开始到年收入相较于每位患者的基线水平下降95%的时间。此外,还研究了治疗时间与社会福利增加(病假、残疾抚恤金)之间的关联。使用Cox模型对性别、发病年龄、教育程度、家庭状况、出生国家、居住地区和残疾情况进行了校正。

结果

较晚开始治疗的MS患者达到该结局的风险更高——那些在MS发病2年后开始治疗的患者更快地失去了95%的收入(风险比,1.19;95%置信区间,1.04 - 1.37)。此外,延迟治疗组获得100,000瑞典克朗(约10,500欧元)年度补偿的风险更高。

结论

MS早期开始治疗与更好的社会经济结局相关,这补充了先前显示在残疾方面有益的研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c36/7564625/a1950dd91349/10.1177_2055217320959116-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c36/7564625/a1950dd91349/10.1177_2055217320959116-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c36/7564625/a1950dd91349/10.1177_2055217320959116-fig1.jpg

相似文献

1
Importance of early treatment decisions on future income of multiple sclerosis patients.早期治疗决策对多发性硬化症患者未来收入的重要性。
Mult Scler J Exp Transl Clin. 2020 Oct 7;6(4):2055217320959116. doi: 10.1177/2055217320959116. eCollection 2020 Oct-Dec.
2
Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis.与儿童期发病多发性硬化相关的长期社会经济结局。
JAMA Neurol. 2021 Apr 1;78(4):478-482. doi: 10.1001/jamaneurol.2020.5520.
3
Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients.社会保障系统提供的收入和经济补偿与多发性硬化症患者的残疾状况密切相关。
PLoS One. 2015 Dec 22;10(12):e0145435. doi: 10.1371/journal.pone.0145435. eCollection 2015.
4
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.儿童发病多发性硬化症患者延迟治疗对残疾的长期影响:一项前瞻性丹麦队列研究。
Mult Scler Relat Disord. 2020 May;40:101956. doi: 10.1016/j.msard.2020.101956. Epub 2020 Jan 17.
5
The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.早期多发性硬化症治疗对残疾养老金风险的长期影响。
J Neurol. 2018 Mar;265(3):701-707. doi: 10.1007/s00415-018-8764-4. Epub 2018 Feb 1.
6
Sources and level of income among individuals with multiple sclerosis compared to the general population: A nationwide population-based study.与普通人群相比,多发性硬化症患者的收入来源和收入水平:一项基于全国人口的研究。
Mult Scler. 2015 Nov;21(13):1730-41. doi: 10.1177/1352458515570767. Epub 2015 Feb 19.
7
Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis.诊断患有多发性硬化症的劳动年龄段个体的可支配收入轨迹。
Acta Neurol Scand. 2018 Dec;138(6):490-499. doi: 10.1111/ane.13001. Epub 2018 Jul 24.
8
Diagnosis-specific sickness absence and disability pension before and after multiple sclerosis diagnosis: An 8-year nationwide longitudinal cohort study with matched references.多发性硬化症诊断前后的特定疾病缺勤和残疾抚恤金:一项 8 年全国纵向队列研究,有匹配的参照。
Mult Scler Relat Disord. 2020 Jul;42:102077. doi: 10.1016/j.msard.2020.102077. Epub 2020 Apr 13.
9
Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic Risks.伴多发性硬化症的衰老:年龄相关因素与社会经济风险
Front Neurol. 2022 Mar 11;13:818652. doi: 10.3389/fneur.2022.818652. eCollection 2022.
10
Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time.多发性硬化症患者与参照人群相比的收入情况,按受教育程度和职业类型分类:不同时间点的基于人群的队列研究。
BMJ Open. 2019 Jul 11;9(7):e024836. doi: 10.1136/bmjopen-2018-024836.

引用本文的文献

1
Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.多发性硬化症诊断与治疗挑战的细胞和分子证据
J Clin Med. 2023 Jun 26;12(13):4274. doi: 10.3390/jcm12134274.
2
Can we change the natural course of inflammatory bowel disease?我们能否改变炎症性肠病的自然病程?
Therap Adv Gastroenterol. 2023 Apr 17;16:17562848231163118. doi: 10.1177/17562848231163118. eCollection 2023.
3
Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden.

本文引用的文献

1
Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.验证瑞典多发性硬化症登记处:进一步改进药物流行病学评估资源。
Epidemiology. 2019 Mar;30(2):230-233. doi: 10.1097/EDE.0000000000000948.
2
Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.多发性硬化症的临床病程与劳动力缺勤:一项基于人群的纵向研究。
Eur J Neurol. 2019 Apr;26(4):603-609. doi: 10.1111/ene.13863. Epub 2019 Jan 10.
3
Early versus later treatment start in multiple sclerosis: a register-based cohort study.
多发性硬化症早期与晚期开始治疗及其对疾病成本的影响:瑞典一项基于登记的前瞻性队列研究。
Mult Scler J Exp Transl Clin. 2022 Apr 24;8(2):20552173221092411. doi: 10.1177/20552173221092411. eCollection 2022 Apr-Jun.
4
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症患者的基线特征和芬戈莫德对认知功能的影响。
Eur J Neurol. 2021 Dec;28(12):4135-4145. doi: 10.1111/ene.15081. Epub 2021 Oct 12.
早期与晚期多发性硬化症治疗开始时间:基于登记的队列研究。
Eur J Neurol. 2018 Oct;25(10):1262-e110. doi: 10.1111/ene.13692. Epub 2018 Jul 9.
4
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.实践指南推荐摘要:多发性硬化症成人的疾病修正治疗:美国神经病学学会指南制定、传播和实施小组委员会的报告。
Neurology. 2018 Apr 24;90(17):777-788. doi: 10.1212/WNL.0000000000005347.
5
Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?时间在多发性硬化症中至关重要:早期治疗和长期随访能否确保每个人都能从多发性硬化症的最新进展中获益?
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509. Epub 2018 Apr 4.
6
Multiple sclerosis.多发性硬化症。
Lancet. 2018 Apr 21;391(10130):1622-1636. doi: 10.1016/S0140-6736(18)30481-1. Epub 2018 Mar 23.
7
The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.早期多发性硬化症治疗对残疾养老金风险的长期影响。
J Neurol. 2018 Mar;265(3):701-707. doi: 10.1007/s00415-018-8764-4. Epub 2018 Feb 1.
8
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.ECTRIMS/EAN 多发性硬化症药物治疗指南
Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.
9
Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.认知功能是瑞典多发性硬化症患者收入的主要决定因素,其独立于身体残疾。
Mult Scler. 2019 Jan;25(1):104-112. doi: 10.1177/1352458517740212. Epub 2017 Nov 16.
10
New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.欧洲多发性硬化症负担与成本的新见解:瑞典的结果
Mult Scler. 2017 Aug;23(2_suppl):179-191. doi: 10.1177/1352458517708682.